Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
Humar A, Lebranchu Y, Vincenti F, Blumberg EA, Punch JD, Limaye AP, Abramowicz D, Jardine AG, Voulgari AT, Ives J, Hauser IA, Peeters P. Humar A, et al. Among authors: hauser ia. Am J Transplant. 2010 May;10(5):1228-37. doi: 10.1111/j.1600-6143.2010.03074.x. Epub 2010 Mar 26. Am J Transplant. 2010. PMID: 20353469 Free article. Clinical Trial.
Response to questions regarding the design and results of the IMPACT trial.
Humar A; IMPACT Investigators Steering Committee; Peeters P, Abramowicz D, Humar A, Lebranchu Y, Hauser I, Jardine A, Limaye AP, Vincenti F, Punch JD, Blumberg E. Humar A, et al. Am J Transplant. 2011 Jan;11(1):177-8. doi: 10.1111/j.1600-6143.2010.03370.x. Am J Transplant. 2011. PMID: 21199360 Free article. No abstract available.
Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study.
Humar A, Limaye AP, Blumberg EA, Hauser IA, Vincenti F, Jardine AG, Abramowicz D, Ives JA, Farhan M, Peeters P. Humar A, et al. Among authors: hauser ia. Transplantation. 2010 Dec 27;90(12):1427-31. doi: 10.1097/tp.0b013e3181ff1493. Transplantation. 2010. PMID: 21197713 Clinical Trial.
Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study.
Lehner F, Budde K, Zeier M, Wüthrich RP, Reinke P, Eisenberger U, Mühlfeld A, Arns W, Stahl R, Heller K, Witzke O, Wolters HH, Suwelack B, Klehr HU, Stangl M, Hauser IA, Nadalin S, Porstner M, May C, Paulus EM, Sommerer C; ZEUS Study Investigators. Lehner F, et al. Among authors: hauser ia. Transpl Int. 2014 Nov;27(11):1192-204. doi: 10.1111/tri.12411. Epub 2014 Aug 20. Transpl Int. 2014. PMID: 25070687 Free article. Clinical Trial.
Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy.
Sommerer C, Duerr M, Witzke O, Lehner F, Arns W, Kliem V, Ackermann D, Guba M, Jacobi J, Hauser IA, Stahl R, Reinke P, Rath T, Veit J, Mehrabi A, Porstner M, Budde K; HERAKLES Study Group. Sommerer C, et al. Among authors: hauser ia. Am J Transplant. 2018 Dec;18(12):2965-2976. doi: 10.1111/ajt.14897. Epub 2018 Jun 3. Am J Transplant. 2018. PMID: 29722128 Free article. Clinical Trial.
141 results